🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today we announced presentation of Phase 2 study data of investigational compound NBI-1117568, including significant improvement in symptoms and overall severity, and new data on safety and tolerability. NBI-‘568 is the first and only investigational oral muscarinic M4 selective

Major depression is one of the most common mental health conditions in the United States, and it can affect all aspects of life, including relationships with family, friends and community. Major depressive disorder is a depression that persists nearly daily for at least two

Today we announced new data from the Phase 4 KINECT-PRO™ open-label study that evaluated physical, social and emotional functioning in patients with tardive dyskinesia. KINECT-PRO is the first and only study to specifically evaluate and present the effects of a VMAT2 inhibitor

We’re excited to announce our partnership with Allie LaForce on “More Than HD,” an educational initiative that aims to increase awareness and understanding of Huntington’s Disease, including HD chorea, and provide resources to the HD community. Allie’s personal experience with

June is #PrideMonth. We celebrate the strength, achievements and contributions of the LGBTQ+ community. Today and every day, Neurocrine stands with our LGBTQ+ colleagues, patients, and partners as a community fully committed to the values of belonging, respect, and empowerment.

We’re excited to welcome Lewis Choi as our Chief Information Officer. With 25 years of experience in information technology and artificial intelligence, Lewis will be responsible for driving the vision and long-term strategic direction of Neurocrine’s technology initiatives. Read

We’ve partnered with Psych Congress Network on a sponsored podcast featuring Dr. Craig Chepke and a patient living with tardive dyskinesia. The episode delves into the patient’s experience with TD, highlighting the impact that involuntary movements can have on physical and

Neurocrine is honored to sponsor the NAMI NAMICon 2025 virtual conference, centered on this year’s theme: “Meeting You Where You Are.” During the conference, connect with a community of mental health advocates and allies who are committed to turning awareness into

June is Congenital Adrenal Hyperplasia (CAH) Awareness Month. CAH is a rare genetic condition that results from an enzyme deficiency that alters the production of adrenal hormones that are essential for life. This CAH Awareness Month, we recognize and stand with members of the

Today we honor #Juneteenth, commemorating the emancipation of enslaved people in the United States. Juneteenth serves as both recognition and celebration to the Black community’s historic freedom and joy.

Today we announced the presentation of new analyses from a Phase 4 randomized withdrawal study measuring health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment on a VMAT2 inhibitor.

This #CAHAwarenessMonth, show your support by becoming informed about congenital adrenal hyperplasia (CAH). Visit WhatTheCAH.com to download CAH awareness images for use on your social media channels. #cahawareness #whatthecah @whatthecah #raredisease

We are proud to partner with Allie LaForce – journalist, sportscaster, and Huntington’s disease awareness advocate – on the “More Than HD” educational initiative. More Than HD was created to help people living with Huntington’s disease and their caregivers following an HD

Two of our scientists, Vice President of Research Fiona Scott and Vice President of Chemistry Research Nicole Harriott, visited government officials at our nation’s capital during the PhRMA Annual Working for Cures Federal Researcher Fly-In. Fiona and Nicole represented

Neurocrine is a proud sponsor of HDSA's Annual Convention. This year’s convention will bring together individuals affected by Huntington’s Disease, their families, caregivers, healthcare professionals, and advocates to exchange knowledge, personal experiences, and build hope for

Today we presented new post-hoc patient-reported data analyses from the KINECT®-HD study at the 2025 Advanced Therapeutics in Movement Disorders & Related Disorders Congress. This study assessed the cognitive and motor-related challenges associated with Huntington’s disease

Welcome, Summer 2025 Interns! We’re excited to welcome 37 talented interns to our team this summer. They’ll gain hands-on experience, receive mentorship, and grow through real-world projects and professional networking. Our interns are working in departments like research &

Today we shared news of a Phase 1 study initiation for NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist. NBIP-01435 is an investigational compound administered as a subcutaneous injection for the potential treatment of congenital adrenal

Today we celebrate the Fourth of July and the values that unite us: freedom, tenacity, and the spirit of possibility. Wishing everyone a safe and festive holiday!